Our team in Nice

Dr. Déborah Aloi, a board-certified radiation oncologist, is primarily specialized in pediatric radiation therapy, particularly in the treatment of solid tumors and hematologic cancers. At the Antoine Lacassagne Center, she also designs treatment plans using proton therapy as well as other external radiation therapy methods for patients with ocular cancers. Her expertise allows for precise tumor targeting while preserving surrounding healthy tissues to the greatest extent possible.

Pr. Stéphanie Baillif is Head of the Ophthalmology Department at Pasteur 2 Hospital in Nice and holds the Chair of Ophthalmology at the Faculty of Medicine of Nice. She is a specialist in medical and surgical diseases of the retina, performing endoresection following proton therapy, and managing complications such as radiation-induced maculopathy.

Robert Ballotti is a Research Director at the Mediterranean Center for Molecular Medicine (C3M), part of Université Côte d’Azur. He co-leads a research team with Corine Bertolotto, focusing on ocular and cutaneous melanomas. A pioneer in identifying key genes involved in melanoma oncogenesis, Robert Ballotti currently serves on the Scientific Advisory Board of the LABEX Signalife program.

Corine Bertolotto is a Research Director at the Mediterranean Center for Molecular Medicine (C3M), part of Université Côte d’Azur. She co-leads a research team with Robert Ballotti, focusing on ocular and cutaneous melanomas. She chairs one of the National Expert Committees of the Ligue contre le Cancer.

Dr. Jean-Pierre Caujolle is specialized in ocular oncology, the branch of medicine focused on eye tumors. He is internationally recognized for his expertise in diagnosing and treating conjunctival tumors.

Dr. Agnès Ducoulombier is a medical oncologist working at the Antoine Lacassagne Center, specializing in sarcoma and metastatic uveal melanoma.

Dr. Anaïs Groulier, a board-certified radiation oncologist, is primarily specialized in ocular tumors, breast cancer and sarcomas radiation therapy. At the Antoine Lacassagne Center, she also designs treatment plans using proton therapy as well as other external radiation therapy methods for patients with ocular cancers. Her expertise allows for precise tumor targeting while preserving surrounding healthy tissues to the greatest extent possible.

Pr. Sandra Lassalle is a specialist in anatomical and cytopathology, a medical discipline dedicated to the microscopic analysis of tissue and tumor samples. This work enables the establishment of a diagnosis and the identification of key prognostic factors, helping to guide therapeutic decisions. She is recognized as a national authority and a European expert in ophthalmic pathology.

Dr. Delphine Marotte, a board-certified radiation oncologist, is specialized ocular cancers. At the Antoine Lacassagne Center, she designs treatment plans using proton therapy as well as other external radiation therapy methods for patients with ocular cancers. Her expertise allows for precise tumor targeting while preserving surrounding healthy tissues to the greatest extent possible.

Dr. Arnaud Martel is a specialist in oculoplastics, a field focused on the treatment of diseases affecting the eyelids, orbit, and lacrimal pathways. He manages and operates on patients with intraocular tumors (primarily uveal melanoma), eyelid tumor, orbital tumors, and tumors of the ocular adnexa (lacrimal gland, nasolacrimal duct). His surgical procedures include both tumor excision and reconstructive surgery, for example following surgery or radiotherapy.

Dr. Célia Maschi is an ophthalmologist specializing in ocular oncology and holds an interuniversity diploma in ocular oncology. She provides dedicated consultations for suspicious eye lesions and performs surgical procedures for patients with intraocular and ocular surface tumors.

Dr. Sacha Nahon-Estève is specialized in vitreoretinal surgery and ocular oncology. He manages patients with conjunctival and intraocular tumors, both medically and surgically. His procedures include tumor excision as well as the placement of localization systems prior to proton therapy.